Free Trial

Regulus Therapeutics Q1 2024 Earnings Report

Regulus Therapeutics logo
$1.53 -0.06 (-3.77%)
(As of 05:45 PM ET)

Regulus Therapeutics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.15
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Regulus Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Regulus Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Regulus Therapeutics Earnings Headlines

A Simple Trading Strategy You Should Know
It’s no secret, I love big, juicy options trades. But when you’re chasing the BIG fish, you gotta have a way to target some steady, consistent returns in there as well. Check out the $100 Challenge This Chris Pulver, he’s isolated a way for everyday folks to target $100-$150 a day in the stock market, starting with just $1,000 or so. And while we cannot promise future returns or against losses, It’s the perfect supplement to more aggressive options strategies… And right now, everyone needs more cash in this economy.
Regulus Therapeutics Reports Q3 2024 Financial Results
See More Regulus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Regulus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regulus Therapeutics and other key companies, straight to your email.

About Regulus Therapeutics

Regulus Therapeutics (NASDAQ:RGLS), a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

View Regulus Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings